Big Call: Sanofi, Novo Nordisk, PepsiCo, Accenture

Sanofi has recently presented a very bullish outlook. The French pharmaceuticals company is among the most promising players in the entire pharma sector, thanks to blockbusters like Dupixient and the RSV vaccine Beyfortus, with the stock being fundamentally attractive as well, showing a P/E ratio of 12.4 for 2025 and a dividend yield of 3.8%. Novo Nordisk has had to endure significant price declines in recent weeks and months. As Novo Nordisk is among the absolute top players, especially in Type II diabetes with Ozempic and in the area of obesity...